BioLine RX Ltd

Predicción y previsión de precio de BioLine RX Ltd (BLRX)

$2.600

-0.151 (-5.80%)Al cierre

Predicciones de precio

1-Day Price Prediction
+0.61%
1-Week Prediction
+0.07%
1-Month Prediction
2026 Prediction
2030 Prediction

Ábrelo en la app para desbloquear previsiones a más largo plazo.

Loading chart…

Predicción y previsión de BLRX por análisis de gráficos similares

Alphio's BLRX stock price prediction model matches the current BioLine RX Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.62 (+0.61%). The 1-week path is $2.60 (+0.07%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

¿Debería comprar acciones de BioLine RX Ltd?

Currently, BioLine RX Ltd (BLRX) is not a strong buy due to its recent performance and financial instability. The stock price is at $2.60, with a 1-year change of -30.67%, indicating a significant decline over the past year. Additionally, the RSI is at 36.368, suggesting that the stock is nearing oversold territory but is not yet a clear buy signal. The forward P/E ratio is extremely high at 93.46, which raises concerns about valuation. The main risk is the company's negative net income, which was -$2.24 million in the last quarter, indicating ongoing financial struggles. Overall, while there are some positive indicators, such as a recent earnings beat and revenue growth, the financial instability and high valuation suggest that investors should hold off on buying until there are clearer signs of recovery.

BLRX cerró en $2.60 el Friday, tras bajar -5.80%

BioLine RX Ltd (BLRX) last closed at $2.6, losing -5.80%. These facts feed the 1-day and 1-week BLRX price prediction above.

Consenso de analistas

BioLine RX Ltd (BLRX): 4 comprar, 0 mantener, 0 vender. Perspectiva: Strong Buy.

Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.

Strong sellSellNeutralBuyStrong buy
Strong buy
Sell
0
Buy
4

Factores de la previsión

Los factores de la previsión de BioLine RX Ltd (BLRX) combinan patrones gráficos similares, estacionalidad y medias móviles.

Similar patterns

Negative

Bearish

Seasonality

Negative

Bearish

SMA 20

Negative

Bearish

SMA 200

Negative

Bearish

Patrones gráficos similares

Acciones cuya trayectoria reciente más se parece a la de BLRX, ordenadas por similitud.

Análisis de estacionalidad de BLRX

Historically the probability of a positive August return for BLRX is 7.94%. January offers the highest probability of a positive month at 36.07%, while September is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.

Loading chart…

Proyecciones de precio a 10 años de BLRX

MesPrecio mínimoPrecio medioPrecio máximoROI potencial
Aug 2026$3.45$3.96$4.54+52.38%
Sep 2026$4.59$4.98$5.00+91.53%
Oct 2026$4.57$4.89$5.21+87.99%
Nov 2026$4.47$4.73$5.11+81.96%
Dec 2026$4.26$4.62$4.97+77.64%

En 2026, se proyecta que BioLine RX Ltd (BLRX) oscile entre $3.45 y $5.21.

Previsión mensual de BioLine RX Ltd para 2026

Previsión de BLRX para Aug de 2026
ROI potencial: 52.38%

En Aug de 2026, se proyecta que BioLine RX Ltd promedie $3.96, con un mínimo de $3.45 y un máximo de $4.54.

Previsión de BLRX para Sep de 2026
ROI potencial: 91.53%

En Sep de 2026, se proyecta que BioLine RX Ltd promedie $4.98, con un mínimo de $4.59 y un máximo de $5.00.

Previsión de BLRX para Oct de 2026
ROI potencial: 87.99%

En Oct de 2026, se proyecta que BioLine RX Ltd promedie $4.89, con un mínimo de $4.57 y un máximo de $5.21.

Previsión de BLRX para Nov de 2026
ROI potencial: 81.96%

En Nov de 2026, se proyecta que BioLine RX Ltd promedie $4.73, con un mínimo de $4.47 y un máximo de $5.11.

Previsión de BLRX para Dec de 2026
ROI potencial: 77.64%

En Dec de 2026, se proyecta que BioLine RX Ltd promedie $4.62, con un mínimo de $4.26 y un máximo de $4.97.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis